John Reed, J&J’s EVP of innovative medicine
December 5, 2023 07:15 AM ESTUpdated 07:44 AM
R&D
Pharma

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

Drew Armstrong

Executive Editor

John­son & John­son is lay­ing out its drug de­vel­op­ment am­bi­tions un­der its new R&D chief, pro­ject­ing that it will bring in bil­lions of dol­lars in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times